<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00565760</url>
  </required_header>
  <id_info>
    <org_study_id>Q8003-010</org_study_id>
    <nct_id>NCT00565760</nct_id>
  </id_info>
  <brief_title>Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain</brief_title>
  <official_title>A Double-Blind, Multi-Center Extension Study to Evaluate the Safety and Efficacy of Q8003 in Patients With Acute Moderate to Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QRxPharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QRxPharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 double-blind, multiple dose safety extension study of Q8003 administered at&#xD;
      daily doses up to 36 mg morphine/24 mg oxycodone (Q8003 36mg/24mg) over a treatment period of&#xD;
      up to 4 weeks. Patients with acute moderate to severe pain who have completed participation&#xD;
      in one of the designated QRxPharma, Inc. acute pain lead-in studies will be eligible for this&#xD;
      trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The currently designated acute pain lead-in study is Study Q8003-007, which is a safety and&#xD;
      efficacy study of Q8003 in the management of post-bunionectomy pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: adverse events</measure>
    <time_frame>Up to 4 weeks with 3 weeks follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: difference in pain intensity scores from baseline</measure>
    <time_frame>Up to 4 weeks with 3 weeks follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Acute Moderate to Severe Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Q8003</intervention_name>
    <description>Capsules</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has completed participation in one of the designated eligible QRxPharma, Inc.&#xD;
             acute pain lead-in studies.&#xD;
&#xD;
          -  Patient has a BMI ≤35.&#xD;
&#xD;
          -  Patient will anticipate taking the first dose of study medication in this Extension&#xD;
             Study no longer than 24 hours after taking the final dose of study medication in the&#xD;
             lead-in study.&#xD;
&#xD;
          -  Patient is in good health as determined by the Investigator via physical examination&#xD;
             at the Extension Study Baseline Visit.&#xD;
&#xD;
          -  If female, patient is at least one year post-menopausal (defined as one year without&#xD;
             menses), surgically sterile (must be documented), or practicing effective&#xD;
             contraception, in the opinion of the Investigator, and be willing to continue to use&#xD;
             effective contraception for the duration of participation in the study.&#xD;
&#xD;
          -  If female, patient is non-lactating, and if of child-bearing potential, has a negative&#xD;
             urine pregnancy test result at Baseline Visit.&#xD;
&#xD;
          -  Patient has a pulse-oximetry measurement ≥95%, a respiration rate ≥12 breaths/minute,&#xD;
             systolic blood pressure ≥100 mm Hg, and diastolic blood pressure ≥50 mm Hg at the&#xD;
             Extension Study Baseline Visit.&#xD;
&#xD;
          -  Patient is willing to refrain from driving throughout the duration of participation in&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has acute asthma, head injury, elevated intracranial pressure, convulsive&#xD;
             states, congestive heart failure (NYHA classification of III or IV), current cardiac&#xD;
             arrhythmia, current transient cerebral ischemic attacks, current uncontrolled unstable&#xD;
             co-existent systemic disease, serious intercurrent illness, other medical condition,&#xD;
             laboratory abnormality, or extenuating circumstance that, in the opinion of the&#xD;
             Investigator, would preclude participation in the study.&#xD;
&#xD;
          -  Patient has allergy, hypersensitivity, or contraindications to opioids.&#xD;
&#xD;
          -  Patient has poorly controlled hypertension (systolic blood pressure &gt;180 mm Hg or&#xD;
             diastolic blood pressure &gt;95 mm Hg despite antihypertensive medication) at the&#xD;
             Extension Study Baseline Visit.&#xD;
&#xD;
          -  Patient is currently taking tramadol or anticipates taking tramadol during the course&#xD;
             of the study.&#xD;
&#xD;
          -  Patient is currently taking antipsychotic drugs, monoamine oxidase inhibitors, muscle&#xD;
             relaxants, or medications for the treatment of depression.&#xD;
&#xD;
          -  Patient is currently taking any opioid analgesic other than Q8003 or other opioid&#xD;
             study medication, or anticipates taking any opioid analgesic other than Q8003 or other&#xD;
             opioid study medication during the course of the study.&#xD;
&#xD;
          -  Patient is at high risk of addiction: patient has a history of substance abuse&#xD;
             (excluding nicotine or caffeine), a family history of substance abuse, or a history of&#xD;
             adverse consequences related to substance abuse including legal issues.&#xD;
&#xD;
          -  Patient has a history of drug or alcohol use or dependence that, in the opinion of the&#xD;
             Investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
          -  Patient has any medical, psychological, cognitive, social and/or legal conditions that&#xD;
             could, in the opinion of the Investigator, compromise patient safety or interfere with&#xD;
             the ability of the patient to give informed consent and/or comply with all study&#xD;
             requirements, including the necessary time commitment.&#xD;
&#xD;
          -  Patient has received any investigational medication within 30 days prior to the first&#xD;
             dose of study drug in this study other than Q8003 or is scheduled to receive any&#xD;
             investigational drug other than Q8003 during the course of this study.&#xD;
&#xD;
          -  Patient has previously been admitted to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Stern, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>QRxPharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Regional Center for Foot and Ankle Care</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scirex Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>November 28, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <disposition_first_submitted>August 25, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 25, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 30, 2010</disposition_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute</keyword>
  <keyword>Pain</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

